Brad S. Kahl

Also affiliated with Washington University in St. Louis, Jewish Hospital

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 2%percentile

2.1Author DataRank

Indexed papers

3in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 3 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

The Lymphoma Epidemiology of Outcomes cohort study: Design, baseline characteristics, and early outcomes

American Journal of Hematology(2024)10.1002/ajh.27202

Top 10%

2.1DataRank

Top 10%24 citations

Matthew J. Maurer, Brian K. Link, Andrew L. Feldman, Thomas M. Habermann, David L. Jaye +38 more

Papers

Driven by 49 papers — median percentile 90. Top paper: “Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma”.

Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma

Journal of Clinical Oncology(2020)10.1200/jco.20.00303

N/A

5.0DataRank · unranked

152 citations

Kieron Dunleavy, Jeremy S. Abramson, Bayard L. Powell, Brian K. Link, Prapti A. Patel +19 more

Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 Clinical Trial

Blood(2020)10.1182/blood.2019003277

N/A

3.7DataRank · unranked

95 citations

Mei‐Yin C. Polley, Michael V. Knopp, Nathan C. Hall, Lale Kostakoglu, Jun Zhang +14 more

Nivolumab+AVD in Advanced-Stage Classic Hodgkin’s Lymphoma

New England Journal of Medicine(2024)10.1056/nejmoa2405888

N/A

3.4DataRank · unranked

211 citations

Michael LeBlanc, Sharon M. Castellino, Hongli Li, Sarah C. Rutherford, Andrew M. Evens +42 more

Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial

The Lancet Haematology(2020)10.1016/s2352-3026(20)30221-0

N/A

3.3DataRank · unranked

142 citations

Fangxin Hong, Richard F. Ambinder, Jonathon B. Cohen, Michael J. Robertson, Kevin A. David +12 more

The Lymphoma Epidemiology of Outcomes cohort study: Design, baseline characteristics, and early outcomes

American Journal of Hematology(2024)10.1002/ajh.27202

Top 10%

2.1DataRank

Top 10%24 citations

Matthew J. Maurer, Brian K. Link, Andrew L. Feldman, Thomas M. Habermann, David L. Jaye +38 more

Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-20-4575

N/A

1.7DataRank · unranked

56 citations

Brian Hess, Veronika Bachanová, Nancy L. Bartlett, Melissa M. Berrien-Elliott, Ethan McClain +21 more

The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee

Blood(2022)10.1182/blood.2022015851

N/A

1.1DataRank · unranked

1538 citations

Elaine S. Jaffe, James R. Cook, Leticia Quintanilla‐Martínez, Steven H. Swerdlow, Kenneth C. Anderson +68 more

A Three-Arm Randomized Phase II Study of Bendamustine/Rituximab with Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-1345

N/A

0.851DataRank · unranked

22 citations

Fangxin Hong, Thomas M. Habermann, Ranjana H. Advani, Randy D. Gascoyne, Thomas E. Witzig +11 more

Mutations associated with progression in follicular lymphoma predict inferior outcomes at diagnosis: Alliance A151303

Blood Advances(2023)10.1182/bloodadvances.2023010779

N/A

0.760DataRank · unranked

24 citations

Kilannin Krysiak, Cody A. Ramirez, Matthew Mosior, Marcus P. Watkins, Felicia Gomez +18 more

Myeloablative vs nonmyeloablative consolidation for primary central nervous system lymphoma: results of Alliance 51101

Blood Advances(2024)10.1182/bloodadvances.2023011657

N/A

0.691DataRank · unranked

26 citations

Sharmila Giri, Amy S. Ruppert, Susan M. Geyer, Scott E. Smith, Nimish Mohile +11 more

Treatment patterns and outcomes of patients with relapsed or refractory follicular lymphoma receiving three or more lines of systemic therapy (LEO CReWE): a multicentre cohort study

The Lancet Haematology(2022)10.1016/s2352-3026(22)00033-3

N/A

0.628DataRank · unranked

65 citations

Melissa C. Larson, Julianne J. Lunde, Thomas M. Habermann, Izidore S. Lossos, Yucai Wang +19 more

Distinct autoantibody profiles across checkpoint inhibitor types and toxicities

OncoImmunology(2024)10.1080/2162402x.2024.2351255

N/A

0.560DataRank · unranked

10 citations

Mitchell S. von Itzstein, Farjana Fattah, Jialiang Liu, Chengsong Zhu, Yang Xie +6 more

Defining primary refractory large B-cell lymphoma

Blood Advances(2024)10.1182/bloodadvances.2024012760

N/A

0.524DataRank · unranked

32 citations

Raphael Mwangi, Yucai Wang, Arushi Khurana, Matthew J. Maurer, Amy Ayers +15 more

Neoantigen landscape supports feasibility of personalized cancer vaccine for follicular lymphoma

Blood Advances(2024)10.1182/bloodadvances.2022007792

N/A

0.497DataRank · unranked

13 citations

Michelle Becker‐Hapak, Kartik Singhal, David A. Russler‐Germain, Felix Frenkel, Erica K. Barnell +28 more

Vitamin D in patients with low tumor-burden indolent non-Hodgkin lymphoma treated with rituximab therapy (ILyAD): a randomized, phase 3 clinical trial

EClinicalMedicine(2024)10.1016/j.eclinm.2024.102959

N/A

0.465DataRank · unranked

9 citations

Michael T. Brady, Myla Strawderman, Brad S. Kahl, Izidore S. Lossos, Jonathon B. Cohen +13 more

NIVOLUMAB(N)‐AVD IMPROVES PROGRESSION‐FREE SURVIVAL COMPARED TO BRENTUXIMAB VEDOTIN(BV)‐AVD IN ADVANCED STAGE (AS) CLASSIC HODGKIN LYMPHOMA (HL): RESULTS OF SWOG S1826

Hematological Oncology(2023)10.1002/hon.3163_5

N/A

0.464DataRank · unranked

21 citations

Michael LeBlanc, Sharon M. Castellino, Huilin Li, Sarah C. Rutherford, Andrew M. Evens +41 more

Identification of genetic subtypes in follicular lymphoma

Blood Cancer Journal(2024)10.1038/s41408-024-01111-w

N/A

0.458DataRank · unranked

13 citations

Rajesh Detroja, Ting Liu, Keren Isaev, Anjali Silva, Verena Passerini +28 more

ECOG-ACRIN E1411 randomized phase 2 trial of bendamustine-rituximab (BR)-based induction followed by rituximab (R) ± lenalidomide (L) consolidation for Mantle cell lymphoma: Effect of adding bortezomib to front-line BR induction on PFS.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.7503

N/A

0.449DataRank · unranked

19 citations

Opeyemi A. Jegede, Peter Martin, Brian G. Till, Samir Parekh, David T. Yang +15 more

American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and European Society for Blood and Marrow Transplantation Clinical Practice Recommendations for Transplantation and Cellular Therapies in Mantle Cell Lymphoma

Transplantation and Cellular Therapy(2021)10.1016/j.jtct.2021.03.001

N/A

0.425DataRank · unranked

16 citations

Mehdi Hamadani, Ambuj Kumar, Peter Dreger, Jonathan W. Friedberg, Martin Dreyling +29 more

Ultra-Deep Sequencing Reveals the Mutational Landscape of Classical Hodgkin Lymphoma

Cancer Research Communications(2023)10.1158/2767-9764.crc-23-0140

N/A

0.416DataRank · unranked

15 citations

Bryan Fisk, Joshua F. McMichael, Matthew Mosior, Jennifer A. Foltz, Zachary L. Skidmore +26 more

Outcomes of Relapsed or Refractory Diffuse Large B‐Cell Lymphoma Treated With R‐GemOx: A Multicenter Cohort Study

American Journal of Hematology(2025)10.1002/ajh.27630

N/A

0.409DataRank · unranked

10 citations

Jean L. Koff, Melissa C. Larson, Brad S. Kahl, Carla Casulo, Izidore S. Lossos +25 more

Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma

Blood Advances(2022)10.1182/bloodadvances.2022009225

N/A

0.373DataRank · unranked

11 citations

Jeffrey M. Switchenko, Veronika Bachanová, James N. Gerson, Stefan K. Barta, Max J. Gordon +30 more

Metabolic Biomarkers Assessed with PET/CT Predict Sex-Specific Longitudinal Outcomes in Patients with Diffuse Large B-Cell Lymphoma

Cancers(2022)10.3390/cancers14122932

N/A

0.330DataRank · unranked

8 citations

Vanessa A. Sanders, Priyanka Pullarkat, Stephanie Teja, Amber Salter, Marcus P. Watkins +13 more

Is local review of positron emission tomography scans sufficient in diffuse large B‐cell lymphoma clinical trials? A CALGB 50303 analysis

Cancer Medicine(2023)10.1002/cam4.5628

N/A

0.320DataRank · unranked

5 citations

Levi Pederson, Michael V. Knopp, David Poon, Jun Zhang, Brad S. Kahl +10 more

Ultra-Deep Sequencing Reveals the Mutational Landscape of Classical Hodgkin Lymphoma

medRxiv(2021)10.1101/2021.06.25.21258374

N/A

0.269DataRank · unranked

5 citations

Matthew Mosior, Joshua McMichael, Zachary L. Skidmore, Eric J. Duncavage, Christopher A. Miller +24 more

Real-world impact of differences in the WHO and ICC classifications of non-Hodgkin lymphoma: a LEO cohort study analysis

Blood(2024)10.1182/blood.2024025681

N/A

0.269DataRank · unranked

5 citations

Matthew J. Maurer, Thomas M. Habermann, Richard Burack, Jennifer R. Chapman, Jonathon B. Cohen +18 more

Maintenance rituximab in follicular non-Hodgkin lymphoma: facts and controversies

Leukemia & Lymphoma(2012)10.3109/10428194.2011.628061

N/A

0.269DataRank · unranked

5 citations

Sonali M. Smith, Brad S. Kahl, Chadi Nabhan

21 | PROGNOSTIC VALUE OF CIRCULATING TUMOR DNA IN PATIENTS WITH ADVANCED STAGE CLASSIC HODGKIN LYMPHOMA TREATED ON SWOG S1826

Hematological Oncology(2025)10.1002/hon.70093_21

N/A

0.254DataRank · unranked

4 citations

Marcin Kaszkowiak, Michael LeBlanc, Chip Stewart, Alex F. Herrera, J Castillo +18 more

Treatment-related outcomes and patterns of relapse in secondary CNS involvement by large B-cell lymphoma

Blood(2026)10.1182/blood.2025031455

N/A

0.241DataRank · unranked

4 citations

Diva Baggio, Sunwoo Han, Paola Ghione, Imran Nizamuddin, Jahanzaib Khwaja +56 more

Alliance A059102: A randomized phase II U.S. intergroup study of CHO(E)P versus CC-486-CHO(E)P versus duvelisib-CHO(E)P in previously untreated, CD30-negative, peripheral T-cell lymphomas.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.tps7593

N/A

0.241DataRank · unranked

4 citations

Susan M. Geyer, Stefan K. Barta, Jennifer E. Amengual, Travis Dockter, Chadwick Wright +8 more

Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma

Cancer Research Communications(2024)10.1158/2767-9764.crc-24-0252

N/A

0.208DataRank · unranked

3 citations

Hsin-Hui Huang, Opeyemi A. Jagede, Kevin Tuballes, Diane M. Del Valle, Geoffrey Kelly +19 more

Consensus recommendations from the 2024 International Follicular Lymphoma Scientific Workshop

Blood Advances(2025)10.1182/bloodadvances.2025018079

N/A

0.208DataRank · unranked

3 citations

Sarah C. Rutherford, Stephen M. Ansell, Philippe Armand, John P. Leonard, Loretta J. Nastoupil +20 more

Ibrutinib added to standard conditioning and as maintenance therapy following autologous hematopoietic stem cell transplantation for relapsed or refractory activated-B-cell type Diffuse Large B-cell lymphoma: primary analysis of the US intergroup double-blind randomized phase III study Alliance A051301/BMT-CTN 1201

Leukemia & lymphoma/Leukemia and lymphoma(2025)10.1080/10428194.2025.2525982

N/A

0.165DataRank · unranked

2 citations

Olivia Bobek, Eric D. Hsi, Timothy S. Fenske, Patrick J. Stiff, Brian T. Hill +12 more

Neoantigen Landscape Supports Feasibility of Personalized Cancer Vaccine for Follicular Lymphoma

medRxiv(2022)10.1101/2022.01.06.22268805

N/A

0.104DataRank · unranked

1 citations

Felix Frenkel, Michelle Becker‐Hapak, Erica K. Barnell, Ethan McClain, Sweta Desai +27 more

20 | IMPACT OF EBV STATUS AND HISTOLOGY ON OUTCOMES WITH NIVOLUMAB‐AVD VERSUS Bv‐AVD IN PATIENTS ENROLLED ON SWOG S1826

Hematological Oncology(2025)10.1002/hon.70093_20

N/A

0.104DataRank · unranked

1 citations

H. Li, Alex F. Herrera, Anamarija M. Perry, Alexandra E. Kovach, Kelly Davison +13 more

FLIPI24: A Modern Prognostic Model and Clinical Trial Enrichment Tool for Newly Diagnosed Follicular Lymphoma

Journal of Clinical Oncology(2025)10.1200/jco-25-00892

N/A

0.104DataRank · unranked

1 citations

Vít Procházka, Tarec Christoffer El‐Galaly, Christopher R. Flowers, Diego Villa, Emmanuel Bachy +43 more

Therapy for patients with POD24 follicular lymphoma: Treatment patterns and outcomes from the Lymphoma Epidemiology of Outcomes (LEO) Consortium.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.7573

N/A

0.104DataRank · unranked

1 citations

Melissa C. Larson, Jonathan R Day, Thomas M. Habermann, Izidore S. Lossos, Yucai Wang +15 more

Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions

Blood(2021)10.1182/blood.2021012888

N/A

0DataRank · unranked

95 citations

Daniel Reed, Ashley McCook, Jeremy Sen, Christian Barlow, Mary‐Kate Malecek +48 more

Prognostic impact of extranodal disease on PET/CT in follicular lymphoma: results from a validation study with ECOG 2408

Blood Neoplasia(2025)10.1016/j.bneo.2025.100113

N/A

0DataRank · unranked

1 citations

Stephen M. Broski, Zequn Sun, Masha Kocherginsky, Betsy LaPlant, Matthew J. Maurer +10 more

271 | LEUKEMIC NON‐NODAL MANTLE CELL LYMPHOMA IS NOT NECESSARILY EQUIVALENT TO INDOLENT MCL: A REPORT FROM THE LEO COHORT STUDY

Hematological Oncology(2025)10.1002/hon.70094_271

N/A

0DataRank · unranked

0 citations

Yihua Chen, Jeffrey M. Switchenko, Suheil Albert Atallah‐Yunes, Georgio Pongas, Mary P. Watkins +16 more

29 | A COMPARATIVE ANALYSIS OF HISTOLOGIC TRANSFORMATION OF FOLLICULAR LYMPHOMA AT DIAGNOSIS (COMPOSITE LYMPHOMA) AND SEQUENTIALLY TRANSFORMED FOLLICULAR LYMPHOMA

Hematological Oncology(2025)10.1002/hon.70093_29

N/A

0DataRank · unranked

0 citations

Melissa C. Larson, Jonathan Day, Urshila Durani, Mazie Tsang, Dai Chihara +22 more

233 | S1608: RANDOMIZED PHASE II TRIAL COMPARING LENALIDOMIDE/OBINUTUZUMAB AND UMBRALISIB/OBINUTUZUMAB WITH CHEMOIMMUNOTHERAPY IN EARLY PROGRESSING FOLLICULAR LYMPHOMA (POD24)

Hematological Oncology(2025)10.1002/hon.70094_233

N/A

0DataRank · unranked

0 citations

H. Li, Heiko Schöder, Alex F. Herrera, Richard Burack, Brian K. Link +10 more

Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy

Blood Advances(2021)10.1182/bloodadvances.2021004765

N/A

0DataRank · unranked

41 citations

Jeffrey M. Switchenko, Diego Villa, Kami J. Maddocks, Michael C. Churnetski, Alina S. Gerrie +30 more

PHASE II/III STUDY OF R‐MINICHOP ± ORAL AZACITIDINE IN PARTICIPANTS AGE 75 YEARS OR OLDER WITH DIFFUSE LARGE B CELL AND RELATED LYMPHOMAS

Hematological Oncology(2023)10.1002/hon.3166_ot27

N/A

0DataRank · unranked

0 citations

H. Li, Anne Beaven, Paolo F. Caimi, Leandro Cerchietti, Rebecca L. Olin +9 more

Prognostic factors for adult patients with Burkitt lymphoma treated with dose-adjusted EPOCH-R

Blood Advances(2023)10.1182/bloodadvances.2023010223

N/A

0DataRank · unranked

0 citations

Kieron Dunleavy, Jeremy S. Abramson, Brian K. Link, Bayard L. Powell, Christopher Melani +10 more

Data from Bortezomib-Resistant Nuclear Factor-κB Activity in Multiple Myeloma Cells

(2023)10.1158/1541-7786.c.6542187.v1

N/A

0DataRank · unranked

0 citations

Natalie S. Callander, Shelby L. O’Connor, Jihoon Kim, Jae Werndli, Martha Raschko +5 more

A multicenter analysis of the outcomes with venetoclax in patients with relapsed mantle cell lymphoma

Blood Advances(2023)10.1182/bloodadvances.2022008916

N/A

0DataRank · unranked

29 citations

Subir Goyal, Jeffrey M. Switchenko, Jason T. Romancik, Manali Kamdar, Irl Brian Greenwell +17 more

Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study

Blood(2023)10.1182/blood.2023021274

N/A

0DataRank · unranked

47 citations

Nicholas Lambert, Paolo F. Caimi, Mwanasha H. Merrill, Priyanka Pullarkat, Richard Godby +19 more

Prospective SPECT-CT Organ Dosimetry-Driven Radiation-Absorbed Dose Escalation Using the In-111 (111In)/Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) Theranostic Pair in Patients with Lymphoma at Myeloablative Dose Levels

Cancers(2021)10.3390/cancers13112828

N/A

0DataRank · unranked

13 citations

Eric C. Frey, Heather A. Jacene, Brad S. Kahl, Steven Piantadosi, Jesus A. Bianco +8 more

Brad S. Kahl

Indexed papers

Top data-sharing exemplar

Papers